wAIHA
-
News
wAIHA | Rilzabrutinib Receives FDA Breakthrough Therapy Designation
Warm autoimmune haemolytic anaemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells, leading to anemia and other serious complications, such as significant fatigue, dizziness,…
Read More » -
News
wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden. The…
Read More » -
News
NEW STUDY | Pegcetacoplan Shows Potential in Managing CAD and wAIHA
This investigational therapy, which targets complement component C3, has demonstrated the ability to increase haemoglobin levels, reduce haemolysis, and improve fatigue scores, according to the study’s authors. Although not all…
Read More » -
News
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm Autoimmune Hemolytic Anemia (wAIHA) occurs when the body’s immune system mistakenly produces antibodies that attack and destroy its own red blood cells. In this particular case, the patient presented…
Read More » -
News
wAIHA | Fostamatinib May Induce Durable Hemoglobin Response in Subset of Patients
Interestingly, this positive outcome was predominantly observed among participants hailing from North America, Australia, or Western Europe, while those from Eastern Europe didn’t show the same results. The current treatment…
Read More »